Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT3789 as Monotherapy and in Combination With Docetaxel in Participants With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

NCT05639751 is registered in ClinicalTrials.gov with Prelude Therapeutics as lead sponsor.

NCT NCT05639751
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05639751 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT3789 as Monotherapy and in Combination With Docetaxel in Participants With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
Lead sponsor
Prelude Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
May 2, 2023
Completion date
October 1, 2025
Enrollment
135 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, metastatic solid tumor, non-small cell lung cancers, smarca4 gene mutation